Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Disorders of the Male Reproductive System

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Off-clamp and on-clamp robotic-assisted partial nephrectomy in ischemia-sensitive patients: a multicenter propensity score-matched study (RAPN OFF-CLAMP study - UroCCR 187).

Minerva urology and nephrology·2026

Same author

Pembrolizumab After Nephrectomy for High-risk Renal Cell Carcinoma: Real-world Data from a National Early Access Program Registry.

European urology oncology·2026

Same author

Partial Nephrectomy Versus Thermal Ablation for Cystic Renal Tumors: A Registry-Based, Propensity Score Matched Analysis (UroCCR n°177).

Cardiovascular and interventional radiology·2026

Same author

Feasibility and Safety of a Ketogenic Diet During Systemic Therapy for Metastatic Renal Cell Carcinoma: Results from the Cetorein Pilot Study.

Nutrients·2026

Same author

sPaRT2-Minimally Invasive Partial vs Radical Nephrectomy for cT2 Renal Cell Carcinoma: A National Matched-Pair Analysis (UroCCR 235).

The Journal of urology·2026

Same author

Robot-assisted versus open surgery for multiple ipsilateral renal tumors: a multicenter matched cohort study (UroCCR-60).

Journal of robotic surgery·2026

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

High-grade prostate cancer and finasteride.

Souhil Lebdai¹, Pierre Bigot, Abdel-Rahmène Azzouzi

¹Department of Urology, Angers University Hospital, Angers, France.

BJU International

|November 26, 2009

Summary

Finasteride reduces overall prostate cancer risk but may increase high-grade cancer incidence. Further research is needed to understand 5alpha-reductase inhibitors

Area of Science:

Oncology
Urology
Pharmacology

Background:

Prostate cancer is a significant health concern for men globally.
5alpha-reductase (5AR) inhibitors like finasteride show promise in prostate cancer risk reduction.
The Prostate Cancer Prevention Trial (PCPT) investigated finasteride's efficacy and safety.

Purpose of the Study:

To analyze the impact of finasteride on prostate cancer risk, focusing on overall incidence and high-grade tumors.
To investigate potential biases or mechanisms contributing to observed increases in high-grade prostate cancer.
To evaluate the suitability of finasteride for high-grade prostate cancer prevention.

Main Methods:

Review and re-analysis of data from the Prostate Cancer Prevention Trial (PCPT).

More Related Videos

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

Related Experiment Videos

Last Updated: Jun 18, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

Comparison of prostate cancer incidence, including high-grade tumors, between finasteride and placebo groups.

Exploration of hypotheses regarding detection bias and the role of dihydrotestosterone levels.

Main Results:

Finasteride significantly decreased overall prostate cancer risk by 30% compared to placebo.
A statistically non-significant increase in high-grade prostate cancer prevalence was observed in the finasteride group.
The ratio of high-grade cases between groups decreased over time, suggesting potential bias.

Conclusions:

Finasteride effectively reduces overall prostate cancer risk.
The increase in high-grade cancers may be influenced by detection bias or selective inhibition of low-grade tumors.
Finasteride may not be the optimal drug for preventing high-grade prostate cancers due to 5AR isoenzyme profiles.